Shares of Catalent, Inc. (NYSE:CTLT – Get Free Report) have been given an average rating of “Hold” by the seven analysts that are presently covering the company, Marketbeat.com reports. Seven analysts ...

Jefferies investment banker Chris Roop discussed the Big Pharma M&A outlook with Business Insider. Check out the types of ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Following rapid (and pricey) expansion efforts from Novo and Lilly, plus recent shortage updates at the FDA, “positive ...

Novo Holdings' $16.5 billion acquisition of US contract development and manufacturing organisation (CDMO) Catalent has been completed, after months of debate over potential antitrust issues.

A large pharmaceutical company collaborated with DelveInsight to evaluate CDMO companies for API and FD development. DelveInsight provided a comprehensive one-time report benchmarking top contract ...

Research projects that generative AI could boost the pharma and medical-product industries' annual revenues by up to $110 ...

Pharmaceutical Cartridges Market Driven by rising demand for self-administered therapies & advanced drug delivery systems, the <a target ...

The drug and biotech industry had a tough time in the past couple of months after Trump announced the appointment of Robert F ...